PURPOSE: To report a case of psoriasis triggered by anti-tumor necrosis factor-alpha (TNF-α) therapy in a uveitis patient with Behçet's disease. CASE REPORT: A 34-year-old man with established Behçet's disease was started on infliximab therapy for recurrent uveitis and showed an excellent response. After 2 years of infliximab treatment, he developed erythematous scaly plaques on both of his palms and heels. No clinical or serological evidence of infection was found, and there was no personal/family history of psoriasis. Histological examination of one lesion showed that it was consistent with psoriasis. Because of the development of hyperkeratotic skin lesions consistent with guttate psoriasis, the infliximab treatment was discontinued. Six months later, the psoriasis had resolved. CONCLUSIONS: Blockade of TNF-α is an effective treatment for psoriasis as well as Behçet's disease. However, we have to consider new-onset psoriasis as an adverse side effect that can be triggered by anti-TNF-α therapy in Behçet's disease.
PURPOSE: To report a case of psoriasis triggered by anti-tumornecrosis factor-alpha (TNF-α) therapy in a uveitispatient with Behçet's disease. CASE REPORT: A 34-year-old man with established Behçet's disease was started on infliximab therapy for recurrent uveitis and showed an excellent response. After 2 years of infliximab treatment, he developed erythematous scaly plaques on both of his palms and heels. No clinical or serological evidence of infection was found, and there was no personal/family history of psoriasis. Histological examination of one lesion showed that it was consistent with psoriasis. Because of the development of hyperkeratotic skin lesions consistent with guttate psoriasis, the infliximab treatment was discontinued. Six months later, the psoriasis had resolved. CONCLUSIONS: Blockade of TNF-α is an effective treatment for psoriasis as well as Behçet's disease. However, we have to consider new-onset psoriasis as an adverse side effect that can be triggered by anti-TNF-α therapy in Behçet's disease.
Authors: P P Sfikakis; P H Kaklamanis; A Elezoglou; N Katsilambros; P G Theodossiadis; S Papaefthimiou; N Markomichelakis Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: William J Shergy; Reuben A Isern; David A Cooley; John L Harshbarger; J Eugene Huffstutter; Gordon M Hughes; Elizabeth A Spencer-Smith; Allan L Goldman; Sanford H Roth; J Scott Toder; Diana Warner; Adrienne Quinn; Gregory F Keenan; Thomas F Schaible Journal: J Rheumatol Date: 2002-04 Impact factor: 4.666
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321